Psoriatic disease and tuberculosis nowadays

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Balato, Nicola ^a   Di Costanzo, Luisa ^a   Ayala, Fabio ^a   Balato, Anna ^a   Sanduzzi, Alessandro ^a   Bocchino, Marialuisa ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BCG VACCINE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; ISONIAZID; METHOTREXATE; RETINOID; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT;

ANTIBIOTIC PROPHYLAXIS; BIOLOGICAL THERAPY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONTACT DERMATITIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEMATOLOGIC MALIGNANCY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION RISK; INFLAMMATION; INFLAMMATORY DISEASE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; METABOLIC SYNDROME X; MYCOBACTERIUM TUBERCULOSIS; NON MELANOMA SKIN CANCER; NONHUMAN; OBESITY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SKIN TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; RECURRENT DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; PSORIASIS; RECURRENCE; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862304034     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/747204     Document Type: Review

References (94)

1. Perera G. K., Di Meglio P., Nestle F. O., Psoriasis Annual Review of Pathology 2012 7 385 422
2. Sweeney C. M., Tobin A.-M., Kirby B., Innate immunity in the pathogenesis of psoriasis Archives of Dermatological Research 2011 303 10 691 705
3. Saraceno R., Mannheimer R., Chimenti S., Regional distribution of psoriasis in Italy Journal of the European Academy of Dermatology and Venereology 2008 22 3 324 329 (Pubitemid 351247422)
4. Christophers E., Psoriasisepidemiology and clinical spectrum Clinical and Experimental Dermatology 2001 26 4 314 320
5. Vena G. A., Altomare G., Ayala F., Berardesca E., Calzavara-Pinton P., Chimenti S., Giannetti A., Girolomoni G., Lotti T., Martini P., Mazzaglia G., Peserico A., Puglisi Guerra A., Sini G., Cassano N., Cricelli C., Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database European Journal of Dermatology 2010 20 5 593 598
6. Davidovici B. B., Sattar N., Jrg P. C., Puig L., Emery P., Barker J. N., Van De Kerkhof P., Sthle M., Nestle F. O., Girolomoni G., Krueger J. G., Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions Journal of Investigative Dermatology 2010 130 7 1785 1796
7. Kimball A. B., Guérin A., Tsaneva M., Yu A. P., Wu E. Q., Gupta S. R., Bao Y., Mulani P. M., Economic burden of comorbidities in patients with psoriasis is substantial Journal of the European Academy of Dermatology and Venereology 2011 25 2 157 163
8. Yu A. P., Tang J., Xie J., Wu E. Q., Gupta S. R., Bao Y., Mulani P. M., Economic burden of psoriasis compared to the general population and stratified by disease severity Current Medical Research and Opinion 2009 25 10 2429 2438
9. Stern R. S., Nijsten T., Feldman S. R., Margolis D. J., Rolstad T., Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction Journal of Investigative Dermatology Symposium Proceedings 2004 9 2 136 139 (Pubitemid 38457271)
10. Lebwohl M., Bagel J., Gelfand J. M., Gladman D., Gordon K. B., Hsu S., Kalb R. E., Kimball A. B., Korman N. J., Krueger G. G., Mease P., Morison W. L., Paller A., Pariser D. M., Ritchlin C., Strober B., Van Voorhees A., Weinstein G. D., Young M., Horn L., From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis Journal of the American Academy of Dermatology 2008 59 2 209 217
11. Kimball A. B., Gladman D., Gelfand J. M., Gordon K., Horn E. J., Korman N. J., Korver G., Krueger G. G., Strober B. E., Lebwohl M. G., National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening Journal of the American Academy of Dermatology 2008 58 6 1031 1042
12. Lalvani A., Millington K. A., Screening for tuberculosis infection prior to initiation of anti-TNF therapy Autoimmunity Reviews 2008 8 2 147 152
13. Haake H., Kneke J., Amann K., Vom Dahl J., Janssen U., Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF- therapy for psoriatic arthritis Medizinische Klinik 2007 102 10 852 857 (Pubitemid 47619720)
14. Vaughn B. P., Doherty G. A., Gautam S., Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflammatory Bowel Diseases. In press
15. Chung Y., Chang S. H., Martinez G. J., Yang X. O., Nurieva R., Kang H. S., Ma L., Watowich S. S., Jetten A. M., Tian Q., Dong C., Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 Signaling Immunity 2009 30 4 576 587
16. Damsker J. M., Hansen A. M., Caspi R. R., Th1 and Th17 cells: adversaries and collaborators Annals of the New York Academy of Sciences 2010 1183 211 221
17. Kagami S., Rizzo H. L., Lee J. J., Koguchi Y., Blauvelt A., Circulating Th17, Th22, and Th1 cells are increased in psoriasis Journal of Investigative Dermatology 2010 130 5 1373 1383
18. Fitch E., Harper E., Skorcheva I., Kurtz S. E., Blauvelt A., Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines Current Rheumatology Reports 2007 9 6 461 467 (Pubitemid 350305203)
19. Iwakura Y., Ishigame H., The IL-23/IL-17 axis in inflammation Journal of Clinical Investigation 2006 116 5 1218 1222
20. Naldi L., Gambini D., The clinical spectrum of psoriasis Clinics in Dermatology 2007 25 6 510 518 (Pubitemid 350087596)
21. Balato N., Di Costanzo L., Balato A., Differential diagnosis of psoriasis Journal of Rheumatology 2009 36 83 24 25
22. Lisi P., Differential diagnosis of psoriasis Reumatismo 2007 59 56 60
23. Balasubramaniam P., Berth-Jones J., Erythroderma: 90 skin failure Hospital Medicine 2004 65 2 100 102
24. Puig-Sanz L., Psoriasis, a systemic disease? Actas Dermo-Sifiliograficas 2007 98 6 396 402 (Pubitemid 47251517)
25. Faras M. M., Serrano V., De La Cruz C., Psoriasis and obesity: a review and practical recommendations Actas Dermo-Sifiliograficas 2011 102 7 505 509
26. Gottlieb A. B., Dann F., Comorbidities in patients with psoriasis American Journal of Medicine 2009 122 12 1150 e1
27. Boehncke W. H., Boehncke S., Tobin A. M., Kirby B., The psoriatic march: a concept of how severe psoriasis may drive cardiovascular comorbidity Experimental Dermatology 2011 20 4 303 307
28. Foulkes A. C., Grindlay D. J. C., Griffiths C. E. M., Warren R. B., What's new in psoriasis? an analysis of guidelines and systematic reviews published in 2009-2010 Clinical and Experimental Dermatology 2011 36 6 585 588
29. Tobin A. M., Veale D. J., FitzGerald O., Rogers S., Collins P., O'Shea D., Kirby B., Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis Journal of Rheumatology 2010 37 7 1386 1394
30. Prey S., Paul C., Bronsard V., Puzenat E., Gourraud P.-A., Aractingi S., Aubin F., Bagot M., Cribier B., Joly P., Jullien D., Le Maitre M., Richard-Lallemand M.-A., Ortonne J.-P., Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies Journal of the European Academy of Dermatology and Venereology 2010 24 supplement 2 23 30
31. Balato N., Di Costanzo L., Balato A., Patruno C., Scalvenzi M., Ayala F., Psoriasis and melanocytic naevi: does the first confer a protective role against melanocyte progression to naevi? British Journal of Dermatology 2011 164 6 1262 1270
32. Yeap B. B., Paul Chubb S. A., McCaul K. A., Ho K. K. Y., Hankey G. J., Norman P. E., Flicker L., Associations of igf1 and igfbps 1 and 3 with all-cause and cardiovascular mortality in older men: the health in men study European Journal of Endocrinology 2011 164 5 715 723
33. Damasiewicz-Bodzek A., Kos-Kuda B., Suwaa-Jurczyk B., Somatotrophin axis hormones in patients affected with psoriasis Neuroendocrinology Letters 2005 26 6 724 728
34. Savastano S., Balato N., Gaudiello F., Insulin-like growth factor-1, psoriasis, and inflammation: a ménage trois? European Journal of Inflammation 2011 9 3 277 283
35. Patel R. V., Clark L. N., Lebwohl M., Weinberg J. M., Treatments for psoriasis and the risk of malignancy Journal of the American Academy of Dermatology 2009 60 6 1001 1017
36. Brown S. L., Greene M. H., Gershon S. K., Edwards E. T., Braun M. M., Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis and Rheumatism 2002 46 12 3151 3158 (Pubitemid 35453523)
37. Esser A. C., Abril A., Fayne S., Doyle J. A., Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab Journal of the American Academy of Dermatology 2004 50 5, supplement S75 S77
38. Patkar N. M., Teng G. G., Curtis J. R., Saag K. G., Association of infections and tuberculosis with antitumor necrosis factor alpha therapy Current Opinion in Rheumatology 2008 20 3 320 326 (Pubitemid 351483323)
39. Grijalva C. G., Chen L., Delzell E., Baddley J. W., Beukelman T., Winthrop K. L., Griffin M. R., Herrinton L. J., Liu L., Ouellet-Hellstrom R., Patkar N. M., Solomon D. H., Lewis J. D., Xie F., Saag K. G., Curtis J. R., Initiation of tumor necrosis factor- antagonists and the risk of hospitalization for infection in patients with autoimmune diseases Journal of the American Medical Association 2011 306 21 2331 2339
40. Dommasch E. D., Abuabara K., Shin D. B., Nguyen J., Troxel A. B., Gelfand J. M., The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials Journal of the American Academy of Dermatology 2011 64 6 1035 1050
41. Bordignon V., Bultrini S., Prignano G., Sperduti I., Piperno G., Bonifati C., Filippetti M., Toma L., Latini A., Di Cecio M., Giuliani A., Vocaturo A., Trento E., D'Agosto G., Francesconi F., Cataldo A., Vento A., Cilenti V., Berardesca E., Ameglio F., Cordiali Fei P., Ensoli F., High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer Journal of Biological Regulators and Homeostatic Agents 2011 25 2 213 220
42. Bassukas I. D., Kosmidou M., Gaitanis G., Tsiouri G., Tsianos A. E., Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease Acta Dermato-Venereologica 2011 91 4 444 446
43. Snchez-Regaa M., Dilmé E., Puig L., Bordas X., Carrascosa J. M., Ferran M., Herranz P., Garca-Bustinduy M., Lpez Estebaranz J. L., Alsina M., Rodrguez M. A., Ribera M., Fernndez-Lpez E., Moreno J. C., Belinchn Romero I., Vidal D., Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group Actas Dermo-Sifiliograficas 2010 101 2 156 163
44. Salmon-Ceron D., Tubach F., Lortholary O., Chosidow O., Bretagne S., Nicolas N., Cuillerier E., Fautrel B., Michelet C., Morel J., Puéchal X., Wendling D., Lemann M., Ravaud P., Mariette X., Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry Annals of the Rheumatic Diseases 2011 70 616 623
45. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., Pallot-Prades B., Pouplin S., Sacchi A., Chichemanian R. M., Bretagne S., Emilie D., Lemann M., Lorthololary O., Mariette X., Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry Arthritis and Rheumatism 2009 60 7 1884 1894
46. Fonseca J. E., Canho H., Silva C., Miguel C., Mediavilla M. J., Teixeira A., Castelo W., Nero P., Bernardes M., Bernardo A., Mariz E., Godinho F., Santos M. J., Bogas M., Oliveira M., Saavedra M. J., Barcelos A., Cruz M., Santos R. A., Maurcio L., Rodrigues M., Figueiredo G., Quintal A., Patto J. V., Malcata A., da Silva J. C., Arajo D., Ventura F., Branco J., Queiroz M. V., Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience Acta Reumatolgica Portuguesa 2006 31 3 247 253
47. Snchez-Moya A. I., Dauden E., Incidence of tuberculosis infection in psoriatic patients on anti-tnf therapy: report of a case series with 144 patients Journal of the European Academy of Dermatology and Venereology 2011 25 6 730 733
48. Solovic I., Sester M., Gomez-Reino J. J., Rieder H. L., Ehlers S., Milburn H. J., Kampmann B., Hellmich B., Groves R., Schreiber S., Wallis R. S., Sotgiu G., Schlvinck E. H., Goletti D., Zellweger J. P., Diel R., Carmona L., Bartalesi F., Ravn P., Bossink A., Duarte R., Erkens C., Clark J., Migliori G. B., Lange C., The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement European Respiratory Journal 2010 36 5 1185 1206
49. Perez J. L., Kupper H., Spencer-Green G., Impact of screening for latent TB prior to initiation of anti-TNF therapy in North America and Europe Annals of the Rheumatic Diseases 2005 64 86 90
50. Carmona L., Gmez-Reino J. J., Rodrguez-Valverde V., Montero D., Pascual-Gmez E., Mola E. M., Carreo L., Figueroa M., Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis and Rheumatism 2005 52 6 1766 1772 (Pubitemid 40852885)
51. American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC), Targeted tuberculin skin testing and treatment of latent tuberculosis infection American Journal of Respiratory and Critical Care Medicine 2000 161 4 5221 5247
52. Centers for Disease Control and Prevention (CDC), Tuberculosis associated with blocking agents against tumor necrosis factor-alphaCalifornia, 2002-2003 Morbidity and Mortality Weekly Report 2004 53 30 683 686
53. Menzies D., Interpretation of repeated tuberculin tests: boosting, conversion, and reversion American Journal of Respiratory and Critical Care Medicine 1999 159 1 15 21 (Pubitemid 29036497)
54. Ormerod L. P., Milburn H. J., Gillespie S., Ledingham J., Rampton D., BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- treatment Thorax 2005 60 10 800 805 (Pubitemid 41475202)
55. Lalvani A., Millington K. A., Screening for tuberculosis infection prior to initiation of anti-TNF therapy Autoimmunity Reviews 2008 8 2 147 152
56. Moyo S., Isaacs F., Gelderbloem S., Verver S., Hawkridge A. J., Hatherill M., Tameris M., Geldenhuys H., Workman L., Pai M., Hussey G., Hanekom W. A., Mahomed H., Tuberculin skin test and QuantiFERON assay in young children investigated for tuberculosis in South Africa International Journal of Tuberculosis and Lung Disease 2011 15 9 1176 1181
57. Chung J. H., Han C. H., Kim C. J., Lee S. M., Clinical utility of QuantiFERON-TB GOLD In-Tube and tuberculin skin test in patients with tuberculous pleural effusions Diagnostic Microbiology and Infectious Disease 2011 71 3 263 266
58. Diel R., Loaddenkemper R., Nienhaus A., Evidence-Based comparison of commercial Interferon- Release assays for detecting active TB a metaanalysis Chest 2010 137 4 952 968
59. van Zyl-Smit R. N., Zwerling A., Dheda K., Pai M., Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review PLoS ONE 2009 4 12
60. Bocchino M., Bellofiore B., Matarese A., Galati D., Sanduzzi A., IFN- release assays in tuberculosis management in selected high-risk populations Expert Review of Molecular Diagnostics 2009 9 2 165 177
61. Tsiouri G., Gaitanis G., Kiorpelidou D., Dionysiou A., Efthymiou A., Daskalopoulos G., Constantopoulos S., Bassukas I. D., Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis Dermatology 2009 219 2 119 125
62. Bos J. D., De Rie M. A., Teunissen M. B. M., Piskin G., Psoriasis: dysregulation of innate immunity British Journal of Dermatology 2005 152 6 1098 1107 (Pubitemid 40933406)
63. Katsenos S., Nikolopoulou M., Tsiouri G., Bassukas I. D., Constantopoulos S. H., The challenging evaluation of patients with severe psoriasis for latent tuberculosis: an important indication for IGRA Open Respiratory Medicine Journal 2011 5 1 59 60
64. Chiang Y. Z., Panting K., Dever B., Parslew R. A. G., Clinical applicability of T-cell interferon- release assay for tumour necrosis factor- inhibitor therapy in severe psoriasis Clinical and Experimental Dermatology 2011 36 1 39 41
65. Laffitte E., Janssens J. P., Roux-Lombard P., Thielen A. M., Barde C., Marazza G., Panizzon R. G., Saurat J. H., Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon- release assay vs. tuberculin skin test British Journal of Dermatology 2009 161 4 797 800
66. Chiu H.-Y., Hsueh P.-R., Tsai T.-F., Clinical experience of QuantiFERON-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan British Journal of Dermatology 2011 164 3 553 559
67. Bowerman R. J., Tuberculin skin testing in BCG-vaccinated populations of adults and children at high risk for tuberculosis in Taiwan International Journal of Tuberculosis and Lung Disease 2004 8 10 1228 1233 (Pubitemid 39371836)
68. de Andrade Lima E., de Andrade Lima M., de Lorena V. M.B., de Miranda Gomes Y., Lupi O., Benard G., Evaluation of an IFN-gamma assay in the diagnosis of latent tuberculosis in patients with psoriasis in a highly endemic setting Acta Dermato-Venereologica 2011 91 6 694 697
69. Silva L. C. R., Silveira G. G., Arnone M., Romiti R., Geluk A., Franken K. C. L. M., Duarte A. J. D. S., Takahashi M. D. F., Benard G., Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area Archives of Dermatological Research 2010 302 4 255 262
70. Oon H. H., Chong W. S., Liew C. F., Indeterminate results on the interferon- release assay for tuberculosis screening should not be ignored British Journal of Dermatology 2008 159 4 992 993
71. Bocchino M., Matarese A., Bellofiore B., Giacomelli P., Santoro G., Balato N., Castiglione F., Scarpa R., Perna F., Signoriello G., Galati D., Ponticiello A., Sanduzzi A., Performance of two commercial blood IFN- release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF- treatment European Journal of Clinical Microbiology and Infectious Diseases 2008 27 10 907 913
72. Balato N., Ayala F., Gaudiello F., Monfrecola G., Cimmino G., Ponticiello A., Bocchino M., Matarese A., Sanduzzi A., Comparison of tuberculin skin test and interferon- assays in patients with moderate to severe psoriasis who are candidates for antitumour necrosis factor- therapy British Journal of Dermatology 2008 158 4 847 849 (Pubitemid 351415717)
73. Bellofiore B., Matarese A., Balato N., Gaudiello F., Scarpa R., Atteno M., Bocchino M., Sanduzzi A., Prevention of tuberculosis in patients taking tumor necrosis factor- blockers Journal of Rheumatology 2009 36 83 76 77
74. Haddican M. M., Koo J. Y. M., Is tuberculin skin testing reliable during anti-tumor necrosis factor-alpha therapy? A case report and review of the literature Journal of the American Academy of Dermatology 2009 65 1 195 1197
75. Bartalesi F., Vicidomini S., Goletti D., Fiorelli C., Fiori G., Melchiorre D., Tortoli E., Mantella A., Benucci M., Girardi E., Cerinic M. M., Bartoloni A., QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases European Respiratory Journal 2009 33 3 586 593
76. Garcovich S., Ruggeri A., DAgostino M., Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. Journal of the European Academy of Dermatology and Venereology. In press
77. Matulis G., Jni P., Villiger P. M., Gadola S. D., Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon assay Annals of the Rheumatic Diseases 2008 67 1 84 90
78. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A. M., Prejean M. V., Baron G., Lemann M., Puechal X., Breban M., Berenbaum F., Delchier J. C., Flipo R. M., Dautzenberg B., Salmon D., Humbert M., Emilie D., Meyer O., Falgarone G., Chaussade P., Desreumaux X., Liote F., Claudepierre P., Portier A., Bacchi V. F., Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists Arthritis Research and Therapy 2006 8 4, article no. R114
79. Chen D. Y., Shen G. H., Hsieh T. Y., Hsieh C. W., Lan J. L., Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy Arthritis Care and Research 2008 59 6 800 806
80. Sanchez-Moya A. I., Dauden E., Diagnosing latent tuberculosis infection in patients with psoriasis under anti-tumour necrosis factor- treatment: every new solution breeds new doubts British Journal of Dermatology 2011 164 1 208 209
81. Mazurek G. H., Jereb J., Lobue P., Iademarco M. F., Metchock B., Vernon A., Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States Morbidity and Mortality Weekly Report 2005 54 15 49 55
82. Mazurek G. H., Jereb J., Vernon A., LoBue P., Goldberg S., Castros K., Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infectionUnited States, 2010 Morbidity and Mortality Weekly Report 2010 59 5 1 25
83. National Collaborating Centre for Chronic Conditions, Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control 2006 London, UK Royal College of Physicians
84. HPA Tuberculosis Programme Board (Health Protection Agency), Health Protection Agency position statement: on the use of interferon- release assay (IGRA) tests for tuberculosis (TB): draft for consultation. October 2007
85. Canadian Tuberculosis Committee, Updated recommendations on interferon- release assay for latent tuberculosis infection: an advisory committee statement (ACS) Canada Communicable Disease Report 2008 34 ACS-6 1 13
86. Documento sullutilizzo dei nuovi test immunologici per la diagnosi di infezione tubercolare latente, Elaborato dei Gruppi di Studio Infezioni e Tubercolosi dellAssociazione Italiana Pneumologi Ospedalieri (AIPO) e della Societ Italiana di Medicina Respiratoria (SIMeR), http://www.simernet.it/
87. Fonseca J. E., Lucas H., Canho H., Duarte R., Santos M. J., Villar M., Faustino A., Raymundo E., Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors- March 2008 update Revista Portuguesa de Pneumologia 2008 14 2 271 283 (Pubitemid 351552170)
88. Doherty S. D., Van Voorhees A., Lebwohl M. G., Korman N. J., Young M. S., Hsu S., National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents Journal of the American Academy of Dermatology 2008 59 2 209 217
89. Elkayam O., Balbir-Gurman A., Lidgi M., Rahav G., Weiler-Ravel D., Guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with Tnf- blockers Harefuah 2007 146 3 235 237
90. Mariette X., Salmon D., French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers Annals of the Rheumatic Diseases 2003 62 8 791 (Pubitemid 36886422)
91. Kavanagh P. M., Glimartin J. J., O'Donnell J., O'Flanagan D., Tumour Necrosis Factor-a and tuberculosis: guidance from the National TB Advisory Committee Irish Medical Journal 2008 101 1 6 7
92. Beglinger C., Dudler J., Mottet C., Nicod L., Seibold F., Villiger P. M., Zellweger J. P., Screening for tuberculosis infection before initiation of anti-TNF- therapy Swiss Medical Weekly 2007 137 43-44 621 622 (Pubitemid 350114753)
93. Diel R., Hauer B., Loddenkemper R., Manger B., Krger K., Recommendations for tuberculosis screening before initiation of TNFinhibitor treatment in rheumatic diseases Pneumologie 2009 63 6 329 334
94. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999 American Journal of Respiratory and Critical Care Medicine 2000 161 4 1376 1395